Get the Stockscreener App
15.25
1.49%
-0.23
After Hours:
15.25
Summit Therapeutics Inc stock is traded at $15.25, with a volume of 2.64M.
It is down -1.49% in the last 24 hours and up +16.86% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$15.48
Open:
$15.5
24h Volume:
2.64M
Relative Volume:
0.50
Market Cap:
$11.84B
Revenue:
$220.00K
Net Income/Loss:
$-1.21B
P/E Ratio:
-9.5081
EPS:
-1.6039
Net Cash Flow:
$-387.48M
1W Performance:
-1.10%
1M Performance:
+16.86%
6M Performance:
-22.51%
1Y Performance:
-41.07%
1-Day Range:
$14.86
$15.53
1-Week Range:
$14.86
$16.05
52-Week Range:
$12.55
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
15.25 | 11.84B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Summit Therapeutics (SMMT) Q1 2025 earnings summary - Quartr
Why is SMMT stock tumbling today? - MSN
Summit Therapeutics (SMMT) Jefferies London Healthcare Conference 2025 Summary - Quartr
Price to sales forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update - Stocktwits
Price to book forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 85% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
If You Invested $1,000 in Summit Therapeutics Inc (SMMT) - Stock Titan
Understanding Momentum Shifts in (SMMT) - Stock Traders Daily
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering? - Sahm
Summit Therapeutics Inc Actuals & Estimates (NASDAQ:SMMT) - TradingView
Summit Therapeutics Inc Actuals & Estimates (BMV:SMMT) - TradingView
SMMT Forecast — Price Target — Prediction for 2027 - TradingView
Why Is SMMT Stock Tumbling Today? - Stocktwits
Summit Therapeutics finance chief tops list of public CFO pay in 2025 - CFO.com
Bernstein raises Summit Therapeutics stock price target on trial outlook By Investing.com - Investing.com Australia
Bernstein raises Summit Therapeutics stock price target on trial outlook - Investing.com
Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing - Insider Monkey
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT) - Seeking Alpha
Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Raises Target Price to $9.8 - Moomoo
Summit Therapeutics (SMMT) Q4 2025 earnings summary - Quartr
5 Most Promising Healthcare Stocks According to Wall Street Analysts - Insider Monkey
SMMT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Avoiding Lag: Real-Time Signals in (SMMT) Movement - Stock Traders Daily
Summit rebounds after nearly $50M insider purchase - MSN
Summit Therapeutics Inc (SMMT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Summit Therapeutics Inc (SMMT) Institutional Confidence - TradingKey
Summit Therapeutics Inc (SMMT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Summit Therapeutics Inc (SMMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Summit Therapeutics Inc (SMMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Summit Therapeutics Inc (SMMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Summit Therapeutics Inc (SMMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why Summit Therapeutics Is Staying In The Biotechnology Spotlight? - Kalkine Media
Should Summit Therapeutics’ Canceled US$500 Million Equity Offering Reshape SMMT Investors’ View on Financing Strategy? - Sahm
Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Inc. (SMMT) Investor Outlook: Evaluating A Potential 103.85% Upside - DirectorsTalk Interviews
Summit Therapeutics Raises $500 Million in Public Offering to Support Lung Cancer PipelineGAAP Earnings Report - newsline.com
SMMT Jumps As Summit Therapeutics Rides Ivonescimab Momentum - timothysykes.com
Summit Therapeutics stockholders approve directors and incentive plan - The Globe and Mail
Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering - Insider Monkey
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):